A general practice study investigating the effect of Minocin 50 mg b.d. for 12 weeks in the treatment of acne vulgaris.
In a multicentre general practice open study, 338 acne sufferers were treated with Minocin 50 mg b.d. (254 for 12 weeks). A highly significant improvement trend (p less than 0.0001) was found following analysis of visual analogue scales measuring (i) severity of acne, (ii) area covered by acne, (iii) number of inflamed lesions, (iv) density of acne lesions. Over all, 79% of patients thought the therapy to be effective or very effective; 70% of patients continued on the same therapy after the study period. Mean first improvement was noted by the patients after 4 1/2 weeks of treatment. One hundred and twenty-two patients had taken prior oxytetracycline therapy, of these, ninety-four (77%) stopped oxytetracycline therapy because of lack of efficacy. After treatment of these oxytetracycline failures with Minocin, a highly significant improvement trend (p less than 0.0001) of acne was again seen. In this group, 75% of patients thought the Minocin therapy to be effective or very effective; 69% continued Minocin therapy after the study period. In all, 74% of patients having received prior oxytetracycline thought that Minocin therapy was better than their previous therapy. Ninety-three patients had received either no previous therapy or topical therapy alone. Once again Minocin treatment resulted in a highly significant improvement trend (p less than 0.0001) in the severity of acne. Seventy six (82%) of these patients thought that Minocin therapy was effective or very effective. A total of 73% of patients continued with Minocin therapy following the study period. Adverse events were noted in 6% of patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Cohen
P M
PM
D000152:Acne Vulgaris / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D005194:Family Practice; D005260:Female; D006801:Humans; D008297:Male; D008911:Minocycline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010118:Oxytetracycline / Q000627:therapeutic use; D013754:Tetracyclines / Q000627:therapeutic use*; D013997:Time Factors
D013754:Tetracyclines; D008911:Minocycline; D010118:Oxytetracycline